Nkarta Therapeutics is a developer of cell engineering platform created to build the next generation of cell therapies.
Nkarta Therapeutics has raised $240.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2024.
Nkarta Therapeutics's investors include RA Capital Management, Samsara BioCapital, Janus Henderson Investors, New Enterprise Associates, OrbiMed.
Nkarta Therapeutics is headquartered in South San Francisco, United States.
Nkarta Therapeutics is a developer of cell engineering platform created to build the next generation of cell therapies.
Nkarta Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nkarta Therapeutics — Funding & Investors." VCBacked, March 25, 2024, https://www.vcbacked.co/company/nkarta-therapeutics. Accessed November 12, 2026.
VCBacked. (2024). Nkarta Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/nkarta-therapeutics
{{cite web |title=Nkarta Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nkarta-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Nkarta Therapeutics? Request a listing update